<p>Guardant Health, Inc.（納斯達克代碼：GH - 獲取免費報告）董事會成員梅迪納·曼努埃爾·伊達爾戈於 12 月 8 日（星期一）出售了 1,250 股該公司的股票。股票的平均售價為 105.00 美元，總價值為 131,250.00 美元。交易後，該董事直接持有 797 股公司股票，價值為 83,685 美元。此次交易使其持股比例減少了 61.06%。該交易已在與美國證券交易委員會（SEC）的法律文件中披露，具體內容可通過此鏈接訪問。</p>
<ul>
<li>4 只醫療保健股票大幅上漲——還有更多上漲空間</li>
</ul>
<p>梅迪納·曼努埃爾·伊達爾戈最近還進行了以下交易：</p>
<ul>
<li>在 11 月 7 日（星期五），梅迪納·曼努埃爾·伊達爾戈出售了 1,500 股 Guardant Health 股票。股票的平均售價為 95.19 美元，總價值為 142,785.00 美元。</li>
<li>在 9 月 12 日（星期五），梅迪納·曼努埃爾·伊達爾戈出售了 2,165 股 Guardant Health 股票。股票的平均售價為 54.16 美元，總交易額為 117,256.40 美元。</li>
</ul>
<p>獲取 <strong>Guardant Health</strong> 警報：</p>
<h2>Guardant Health 股價下跌 0.6%</h2>
<p>納斯達克代碼：GH 的股票在週三下跌了 0.59 美元，報 102.62 美元。該公司的交易量為 1,913,708 股，而其平均交易量為 2,231,505 股。該股票的市值為 129.3 億美元，市盈率為-31.97，貝塔係數為 1.58。該股票的 50 日移動平均價格為 87.13 美元，200 日移動平均價格為 64.63 美元。Guardant Health, Inc.的 1 年最低價為 29.91 美元，1 年最高價為 112.43 美元。</p>
<ul>
<li>解讀顛覆：深入凱西·伍德的最新投資</li>
</ul>
<p>Guardant Health（納斯達克代碼：GH - 獲取免費報告）最近在 10 月 29 日（星期三）公佈了其財報。公司報告本季度每股收益（EPS）為-0.39 美元，超出市場共識預期的-0.48 美元，超出幅度為 0.09 美元。在去年同期，公司每股收益為-0.88 美元。該公司的收入同比增長了 38.5%。賣方分析師預計 Guardant Health, Inc.在當前財年將發佈-2.9 的每股收益。</p>
<h2>分析師評級上調與下調</h2>
<p>一些股票研究分析師最近對 GH 股票發佈了報告。TD Cowen 將 Guardant Health 的目標價從 63.00 美元上調至 72.00 美元，並在 9 月 25 日的報告中給予該股票 “買入” 評級。Piper Sandler 將 Guardant Health 的目標價從 60.00 美元上調至 90.00 美元，並在 10 月 22 日的報告中給予該股票 “增持” 評級。摩根士丹利將 Guardant Health 的目標價從 105.00 美元上調至 130.00 美元，並在 12 月 1 日的研究報告中給予該公司 “增持” 評級。Canaccord Genuity Group 在 10 月 30 日的報告中設定了 Guardant Health 的目標價為 100.00 美元。最後，Cowen 在 10 月 30 日的研究報告中重申了對 Guardant Health 股票的 “買入” 評級。23 位研究分析師對該股票給予了 “買入” 評級，1 位分析師給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 80.86 美元。</p>
<ul>
<li>3 只分析師預計價格翻倍的快速成長股票</li>
</ul>
<p><strong>獲取我們關於 Guardant Health 的最新研究報告</strong></p>
<h2>機構資金流入與流出</h2>
<p>一些對沖基金和其他機構投資者最近買入和賣出了該股票的股份。Allworth Financial LP 在第三季度將其在 Guardant Health 的持倉提高了 19.5%。Allworth Financial LP 目前持有 844 股該公司股票，價值 53,000 美元，此前在該期間內購買了 138 股。TD Waterhouse Canada Inc.在第三季度將其在 Guardant Health 的持倉提高了 3.2%。TD Waterhouse Canada Inc.目前持有 4,891 股該公司股票，價值 306,000 美元，此前在上個季度購買了 151 股。Signaturefd LLC 在第二季度將其在 Guardant Health 的持倉提高了 50.5%。Signaturefd LLC 目前持有 635 股該公司股票，價值 33,000 美元，此前在該期間內收購了 213 股。American Century Companies Inc.在第一季度將其在 Guardant Health 的持倉提高了 0.3%。American Century Companies Inc.目前持有 104,206 股該公司股票，價值 4,439,000 美元，此前在該期間內收購了 282 股。最後，PNC Financial Services Group Inc.在第三季度將其在 Guardant Health 的持倉提高了 8.3%。PNC Financial Services Group Inc.目前持有 4,016 股該公司股票，價值 251,000 美元，此前在上個季度收購了 307 股。機構投資者和對沖基金持有該公司 92.60% 的股份。</p>
<h2>Guardant Health 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Guardant Health, Inc.是一家精準腫瘤學公司，在美國和國際上提供血液和組織檢測、數據集和分析。該公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 測試；Guardant360 反應測試；Guardant360 TissueNext 測試；GuardantINFINITY 測試；GuardantConnect，一種為臨牀和生物製藥客户設計的集成軟件解決方案，旨在將接受檢測的患者與具有潛在相關臨牀研究的可操作性改變相連接；GuardantOMNI 測試用於晚期癌症；以及 GuardantINFORM，一個用於各種生物標誌物驅動癌症的腫瘤演變和治療耐藥性的計算機研究平台。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Guardant Health</li>
<li>3 只可以提升您投資組合的家居改善股票</li>
<li>市場動能：3 只有望大幅突破的股票</li>
<li>價值投資：這是一種好的策略嗎？提示：永遠</li>
<li>3 個理由説明凱西的便利店將繼續上漲</li>
<li>市盈率計算：如何評估股票</li>
<li>黃金交叉警報：3 只具有重大上漲潛力的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
<p>在你考慮 Guardant Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Guardant Health 並不在名單上。</p>
<p>雖然 Guardant Health 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Guardant Health 的董事 Medina Manuel Hidalgo 以每股 105 美元的價格出售了 1,250 股，總計 131,250 美元。這次出售使他的持股減少了 61.06%。該股票下跌 0.6%，報 102.62 美元。分析師對該股票給予了 “適度買入” 的評級，目標價格為 80.86 美元。機構投資者已調整了在公司的持倉</p>

<p>Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Medina Manuel Hidalgo sold 1,250 shares of the business's stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.00, for a total value of $131,250.00. Following the transaction, the director directly owned 797 shares in the company, valued at $83,685. The trade was a 61.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Guardant Health, Inc.（納斯達克代碼：GH - 獲取免費報告）董事會成員梅迪納·曼努埃爾·伊達爾戈於 12 月 8 日（星期一）出售了 1,250 股該公司的股票。股票的平均售價為 105.00 美元，總價值為 131,250.00 美元。交易後，該董事直接持有 797 股公司股票，價值為 83,685 美元。此次交易使其持股比例減少了 61.06%。該交易已在與美國證券交易委員會（SEC）的法律文件中披露，具體內容可通過此鏈接訪問。</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只醫療保健股票大幅上漲——還有更多上漲空間</li>
</ul>
</div><p>Medina Manuel Hidalgo also recently made the following trade(s):</p>
<div class="lb-trans"><p>梅迪納·曼努埃爾·伊達爾戈最近還進行了以下交易：</p>
</div><ul>
<li>On Friday, November 7th, Medina Manuel Hidalgo sold 1,500 shares of Guardant Health stock. The shares were sold at an average price of $95.19, for a total value of $142,785.00.</li>
<li>On Friday, September 12th, Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 11 月 7 日（星期五），梅迪納·曼努埃爾·伊達爾戈出售了 1,500 股 Guardant Health 股票。股票的平均售價為 95.19 美元，總價值為 142,785.00 美元。</li>
<li>在 9 月 12 日（星期五），梅迪納·曼努埃爾·伊達爾戈出售了 2,165 股 Guardant Health 股票。股票的平均售價為 54.16 美元，總交易額為 117,256.40 美元。</li>
</ul>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Guardant Health</strong> 警報：</p>
</div><h2>Guardant Health Trading Down 0.6%</h2>
<div class="lb-trans"><h2>Guardant Health 股價下跌 0.6%</h2>
</div><p>Shares of NASDAQ:GH traded down $0.59 on Wednesday, hitting $102.62. The company had a trading volume of 1,913,708 shares, compared to its average volume of 2,231,505. The stock has a market cap of $12.93 billion, a price-to-earnings ratio of -31.97 and a beta of 1.58. The stock has a 50 day moving average price of $87.13 and a 200 day moving average price of $64.63. Guardant Health, Inc. has a 1-year low of $29.91 and a 1-year high of $112.43.</p>
<div class="lb-trans"><p>納斯達克代碼：GH 的股票在週三下跌了 0.59 美元，報 102.62 美元。該公司的交易量為 1,913,708 股，而其平均交易量為 2,231,505 股。該股票的市值為 129.3 億美元，市盈率為-31.97，貝塔係數為 1.58。該股票的 50 日移動平均價格為 87.13 美元，200 日移動平均價格為 64.63 美元。Guardant Health, Inc.的 1 年最低價為 29.91 美元，1 年最高價為 112.43 美元。</p>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解讀顛覆：深入凱西·伍德的最新投資</li>
</ul>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same quarter in the prior year, the company posted ($0.88) EPS. The business's revenue was up 38.5% on a year-over-year basis. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Guardant Health（納斯達克代碼：GH - 獲取免費報告）最近在 10 月 29 日（星期三）公佈了其財報。公司報告本季度每股收益（EPS）為-0.39 美元，超出市場共識預期的-0.48 美元，超出幅度為 0.09 美元。在去年同期，公司每股收益為-0.88 美元。該公司的收入同比增長了 38.5%。賣方分析師預計 Guardant Health, Inc.在當前財年將發佈-2.9 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>A number of equities research analysts have recently issued reports on GH shares. TD Cowen boosted their price objective on Guardant Health from $63.00 to $72.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, September 25th. Piper Sandler lifted their price target on Guardant Health from $60.00 to $90.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, October 22nd. Morgan Stanley boosted their price target on Guardant Health from $105.00 to $130.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, December 1st. Canaccord Genuity Group set a $100.00 price objective on Guardant Health in a report on Thursday, October 30th. Finally, Cowen reiterated a &#34;buy&#34; rating on shares of Guardant Health in a research report on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $80.86.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對 GH 股票發佈了報告。TD Cowen 將 Guardant Health 的目標價從 63.00 美元上調至 72.00 美元，並在 9 月 25 日的報告中給予該股票 “買入” 評級。Piper Sandler 將 Guardant Health 的目標價從 60.00 美元上調至 90.00 美元，並在 10 月 22 日的報告中給予該股票 “增持” 評級。摩根士丹利將 Guardant Health 的目標價從 105.00 美元上調至 130.00 美元，並在 12 月 1 日的研究報告中給予該公司 “增持” 評級。Canaccord Genuity Group 在 10 月 30 日的報告中設定了 Guardant Health 的目標價為 100.00 美元。最後，Cowen 在 10 月 30 日的研究報告中重申了對 Guardant Health 股票的 “買入” 評級。23 位研究分析師對該股票給予了 “買入” 評級，1 位分析師給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，平均目標價為 80.86 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只分析師預計價格翻倍的快速成長股票</li>
</ul>
</div><p><strong>Get Our Latest Research Report on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Guardant Health 的最新研究報告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Allworth Financial LP lifted its position in Guardant Health by 19.5% during the third quarter. Allworth Financial LP now owns 844 shares of the company's stock worth $53,000 after purchasing an additional 138 shares during the period. TD Waterhouse Canada Inc. raised its position in shares of Guardant Health by 3.2% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company's stock valued at $306,000 after buying an additional 151 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company's stock worth $33,000 after acquiring an additional 213 shares during the period. American Century Companies Inc. lifted its holdings in shares of Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company's stock worth $4,439,000 after acquiring an additional 282 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of Guardant Health by 8.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company's stock worth $251,000 after acquiring an additional 307 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近買入和賣出了該股票的股份。Allworth Financial LP 在第三季度將其在 Guardant Health 的持倉提高了 19.5%。Allworth Financial LP 目前持有 844 股該公司股票，價值 53,000 美元，此前在該期間內購買了 138 股。TD Waterhouse Canada Inc.在第三季度將其在 Guardant Health 的持倉提高了 3.2%。TD Waterhouse Canada Inc.目前持有 4,891 股該公司股票，價值 306,000 美元，此前在上個季度購買了 151 股。Signaturefd LLC 在第二季度將其在 Guardant Health 的持倉提高了 50.5%。Signaturefd LLC 目前持有 635 股該公司股票，價值 33,000 美元，此前在該期間內收購了 213 股。American Century Companies Inc.在第一季度將其在 Guardant Health 的持倉提高了 0.3%。American Century Companies Inc.目前持有 104,206 股該公司股票，價值 4,439,000 美元，此前在該期間內收購了 282 股。最後，PNC Financial Services Group Inc.在第三季度將其在 Guardant Health 的持倉提高了 8.3%。PNC Financial Services Group Inc.目前持有 4,016 股該公司股票，價值 251,000 美元，此前在上個季度收購了 307 股。機構投資者和對沖基金持有該公司 92.60% 的股份。</p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p>
<div class="lb-trans"><p>Guardant Health, Inc.是一家精準腫瘤學公司，在美國和國際上提供血液和組織檢測、數據集和分析。該公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 測試；Guardant360 反應測試；Guardant360 TissueNext 測試；GuardantINFINITY 測試；GuardantConnect，一種為臨牀和生物製藥客户設計的集成軟件解決方案，旨在將接受檢測的患者與具有潛在相關臨牀研究的可操作性改變相連接；GuardantOMNI 測試用於晚期癌症；以及 GuardantINFORM，一個用於各種生物標誌物驅動癌症的腫瘤演變和治療耐藥性的計算機研究平台。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Guardant Health</li>
<li>3 只可以提升您投資組合的家居改善股票</li>
<li>市場動能：3 只有望大幅突破的股票</li>
<li>價值投資：這是一種好的策略嗎？提示：永遠</li>
<li>3 個理由説明凱西的便利店將繼續上漲</li>
<li>市盈率計算：如何評估股票</li>
<li>黃金交叉警報：3 只具有重大上漲潛力的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Guardant Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Guardant Health 並不在名單上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Guardant Health 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Guardant Health（納斯達克代碼：GH）的一位董事出售了價值 131,250.00 美元的股票